Trial: 202201008

A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, in patients with therapy refractory metastatic castration resistant prostate cancer


I/II (Cancer Control)

Principal Investigator

Picus, Joel

Disease Site


Learn more about this study at: